Tesla Shares Unaffected As Traders Circulate Alert From CNBC Pro Morgan Stanley Says China’s Didi Crackdown Could Have Implications For Tesla
https://twitter.com/CNBCPro/status/1412804460494180353
BofA Downgrades Fortis On Premium Valuation, Near-Term Pressures
Fortis Inc’s (NYSE: FTS) stock is relatively more expensive than its peers and there seems to be limited upside ahead, “even if additional capex were to materialize within the current plan,” according to BofA Securities.
Why Credit Suisse Is Bullish On Boston Beer Company
A combination of reopenings and seltzer market growth has Credit Suisse bullish on Boston Beer Company, Inc (NYSE: SAM).
The Boston Beer Co. Analyst: Credit Suisse upgraded Boston Beer Co. from Neutral to Outperform and increased the price target from $1,304 to $1,490.
Alibaba’s Position In E-Commerce, Cloud Stronger Than Feared By Wall Street, Says Analyst
Alibaba Group Holding (NYSE: BABA)’s position in e-commerce and cloud markets after it paid up a record $2.8 billion antitrust fine is better-than-feared, according to KeyBanc Capital Markets.
Warren Buffett-Backed Automaker BYD Could Fully Transition To NEVs As Evident From Sale-Numbers, Say Analysts
Chinese legacy automaker BYD Co Ltd (OTC: BYDDF) could transition to a fully new-energy-vehicle portfolio, a Huaxi Securities analyst said, as reported by c
Arrowhead’s Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.
Unprofitable Companies Are Flooding The Market With Stock Offerings: What Does It Mean?
AMC Entertainment Holdings Inc (NYSE: AMC) and GameStop Corp.
Takeaways On Unity Biotech’s Clinical Data From A Bull Analyst
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX).
The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target.
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS).
The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.
What We Know About Apple’s Next iPhone
Apple, Inc.'s (NASDAQ: AAPL) hardware releases, especially the release of its flagship product, the iPhone, are always watched keenly.
And rightfully so: the iPhone fetches over half of the company's total revenues.